-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K0lM7Loka//II5CVS39aO8gPwjKOmjFHhuqhTbmK8PitWOXlUG2uhGSv3p5IrPfe u1DLAK0wWQsKZp2ATzfUAg== 0001169232-02-002111.txt : 20021015 0001169232-02-002111.hdr.sgml : 20021014 20021015161641 ACCESSION NUMBER: 0001169232-02-002111 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020831 FILED AS OF DATE: 20021015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MILLENIA HOPE INC CENTRAL INDEX KEY: 0001060827 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980213828 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-29385 FILM NUMBER: 02789350 BUSINESS ADDRESS: STREET 1: 4055 ST. CATHERINE ST STREET 2: SUITE 142 H3Z 3J8 CITY: MONTREAL QUEBEC STATE: A6 ZIP: 62704 BUSINESS PHONE: 5148465757 MAIL ADDRESS: STREET 1: 4055 ST. CATHERINE ST STREET 2: SUITE 142 H3Z 3J8 CITY: MONTREAL QUEBEC STATE: A6 10-Q 1 d52195_10-q.txt QUARTERLY REPORT Document is copied. MILLENIA HOPE INC. (Exact name of Small Business Issuer as Specified in its Charter) DELAWARE 98-0213828 (state or other Jurisdiction of (I.R.S Employer Incorporation or Organization) Identification No.) 4055 Ste Catherine st. suite 142, Montreal, Quebec H3Z 3J8 (Address of Principal Executive Offices) (514) 846-5757 Issuer's Telephone Number Including Area Code) State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: At August 31, 2002 Issuer had 36,862,695 outstanding shares of Common Stock. INDEX PART I: FINANCIAL INFORMATION Item 1. Financial Statements Consolidated Balance Sheet (Unaudited) at August 31, 2002. Consolidated Statement of Operations (Unaudited) for the three and nine months ended August 31, 2002 and August 31, 2001 and from inception (December 24, 1997) to August 31, 2002. Consolidated Statements of Cash Flows (Unaudited) for the nine months ended August 31, 2002 and August 31, 2001 and from inception (December 24, 1997) to August 31, 2002. Notes to the Financial Statements (Unaudited) Item 2. Plan of Operations PART II. Other Information Item 2. Sale of Unregistered Securities Item 6. Exhibits and Reports on Form SIGNATURES MILLENIA HOPE INC. CONSOLIDATED BALANCE SHEET AT AUGUST 31, 2002 (UNAUDITED) Assets Current Assets Cash and cash equivalents -- Accounts Receivable 220,318 Note Receivable - Related Party 176,064 ---------- Total current assets 396,382 Property and equipment, net 48,915 Other Assets 2,800,000 ---------- Total assets 3,245,297 ========== Liabilities and Shareholder's Equity Current Liabilities Bank Indebtedness 2,939 Accounts payable and accrued liabilities 184,874 Notes payable (principally related parties) 167,816 Other current liabilities 2,500 ---------- Total current liabilities 358,129 Minority Interest 108,293 Shareholder's Equity Common Stock, $.0001 par value; authorized 3,686 70,000,000 shares; issued and outstanding 36,862,695 Warrants 1,393,247 Paid in Capital 6,762,109 Shares Subscriptions receivable (370,469) Cost of Treasury Shares 100 Deficit accumulated during the development stage (5,009,798) ---------- Total Shareholder's Equity 2,778,875 Total liabilities and shareholder's equity $3,245,297 ========== Read the accompanying significant notes to financial statements, which are an integral part of this financial statement MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) CONSOLIDATED STATEMENT OF OPERATIONS FOR THE 3 MONTHS AND NINE MONTHS ENDED AUGUST 31, 2002 AND 2001 FROM INCEPTION (DECEMBER 24, 1997) THROUGH AUGUST 31, 2002 (UNAUDITED)
Three Months Nine Months Inception Ended August 31, Ended August 31, (December 24, 1997) --------------------------- --------------------------- through 2002 2001 2002 2001 August 31, 2002 ----------- ----------- ----------- ----------- -------------- Revenue: 131,800 74,415 317,586 242,879 1,026,205 Cost of Revenues 35,664 31,087 107,914 173,250 521,326 ----------- ----------- ----------- ----------- ----------- 96,136 43,328 209,672 69,629 504,879 Operating expenses: Marketing 56,174 -- 56,174 -- 1,687,792 Patent Rights -- -- -- 624,395 1,005,827 Other Development Costs -- -- 32,400 -- 893,971 Rent 21,696 23,600 64,396 70,800 354,206 Travel -- -- -- 2,675 234,859 Selling, general and administrative expenses 96,690 18,380 219,657 80,589 1,214,477 ----------- ----------- ----------- ----------- ----------- Total operating expenses 174,560 41,980 372,627 778,459 5,391,132 Loss before other income (expense) (78,424) 1,348 (162,955) (708,830) (4,886,253) Other income (expense) (Net) Interest (expense) (Net) (189) (532) (1,192) (2,340) (155,484) Sale by subsidiary of common stock 51,375 -- 51,375 -- 51,375 ----------- ----------- ----------- ----------- ----------- Total other income (expense) 51,186 (532) 50,183 (2,340) (104,109) ----------- ----------- ----------- ----------- ----------- Net Income (Loss) before Minority Interest (27,238) 816 (112,772) (711,170) (4,990,362) Minority Interest in Net Income (Loss) of Subsidiary 20,807 (5,454) 41,841 122 19,435 ----------- ----------- ----------- ----------- ----------- Net (Loss) (48,045) (4,638) (154,613) 711,292 (5,009,798) =========== =========== =========== =========== =========== Basic weighted average common shares outstanding 36,845,681 27,617,515 36,349,895 23,362,600 19,700,802 =========== =========== =========== =========== =========== Basic Loss per common share $ (0.0013) $ (0.0002) $ (0.0043) $ (0.0304) (0.2543) =========== =========== =========== =========== ===========
MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) CONSOLIDATED STATEMENT OF CASH FLOWS FOR NINE MONTHS ENDED AUGUST 31, 2002 AND AUGUST 31, 2001 FROM INCEPTION (DECEMBER 24, 1997) THROUGH AUGUST 31, 2002
Inception Nine Months December 24, 1997) Ended Aug 31 Ended Aug 31 through 2002 2001 August 31, 2002 ------ --------- ---------------- CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) $(154,613) $ 711,292 $(5,009,798) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization 20,145 20,777 103,021 Issuance of stock for general & administrative expenses 96,839 18,750 115,589 Issuance of stock for marketing services -- -- 1,544,215 Issuance of note for other development costs 32,400 124,395 849,626 (subsequently converted to warrants) Interest expense settled with issuance of note -- -- 27,770 (subsequently converted to warrants) Interest expense - related party 9,757 -- 26,842 Interest income - related party (8,565) -- (20,996) Changes in Operating assets and liabilities: Receivables and other Assets (86,645) 42,781 (375,386) Accounts Payable and Accrued Liabilities 31,704 (24,768) 148,520 ------ --------- ----------- Net cash provided by/(used in) operating activities (58,978) (529,357) (2,590,597) CASH FLOWS FROM INVESTING ACTIVITIES: Bank Indebtedness 1,512 -- 2,939 Purchase of Property and equipment -- (667) (128,715) Issuance of stock for subsidiaries cash balance -- -- 40,628 Repayment of subsidiary share subscription receivable -- -- 34,233 Collection of subsidiary share subscription receivable -- -- 83,331 Minority interest portion of net income (loss) of subsidiary 41,841 122 19,435 Deposits on future acquisitions -- 500,000 (1,000,000) ------ --------- ----------- Net cash provided by/(used in) investing activities 43,353 499,455 (948,149) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from: Notes payable, principally related parties -- -- 1,416,045 Issuance of stock 15,625 16,500 957,701 Contribution to Paid in Capital -- -- 1,165,000 ------ --------- ----------- Net cash provided by/(used in) financing activities 15,625 16,500 3,538,746 ------ --------- ----------- Net increase (decrease) in cash and cash equivalents -- (13,402) -- Cash and cash equivalents, beginning of period -- 14,550 -- ------ --------- ----------- Cash and cash equivalents, end of period -- $ 1,148 -- ====== ========= =========== Supplemental Schedule of noncash investing and financing activities: On February 28, 2000, the company issued 4,644,156 warrants to settle the following related party notes: Notes payable (principally related parties) (net of discount) 1,172,648 Long -term debt, less current portion (net of discount) 104,031 Current portion of long term debt ( net of discount) 88,800 Current year interest expense 27,770 --------- 1,393,249
On May 29, 2000, the company issued 5,000,000 shares of common stock in exchange for 35,700,000 shares of Sword Comp-Soft Corp, a Delaware corporation which provides on-line interactive health services through the Internet. The transaction was recorded using the "purchase method" as the registrant acquired 76,54% of Sword Comp-Soft Inc's outstanding shares at May 29, 2000. The following assets were acquired through this transaction: Notes Receivable - 3rd Party 33,600 Notes Receivable - Related Party 34,233 Property and Equipment, net 23,221 The following liabilities were assumed through this transaction: Accounts payable and accrued liabilities 4,500 On April 30, 2000, the company's subsidiary issued 600,000 shares for Equipment valued at $15,000. On October 12, 2001 the company issued 7,000,000 common shares to acquire other assets valued at $2,294,541. On October 12, 2001 the company divested itself of 1,000,000 common shares that it owned of its subsidiary for other assets valued at $5,459. MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AUGUST 31, 2002 (Unaudited) NOTE 1 - BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Millenia Hope Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Article 10 of Regulation S-X. The financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in Millenia Hope Inc.'s on Form 10KSB as filed with the Securities and Exchange Commission. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Note 2 - Revenue Recognition The company currently recognizes revenue in the form of direct sales to the retail market and licensing fees, which are recorded over the life of the licensing agreement using the straight-line method. Currently the company has one agreement with a term of 5 years commencing on January , 1999. The company also recognizes revenue from its subsidiary, providing technology related services, such internet site hosting and software consulting. Revenue is recognized when the service is performed. In December 1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin No. 101 ("SAB 101"), "Revenue Recognition," which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. SAB 101 outlines the basic criteria that must be met to recognize revenue and provide guidance for disclosures related to revenue recognition policies. Management believes that Millenia Hope Inc.'s revenue recognition practices are in conformity with the guidelines of SAB 101. NOTE 3 - NET LOSS PER SHARE Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Options and warrants are not considered since considering such items would have an antidilutive effect. NOTE 4 - GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The company reported a net loss of $(48,045) and $(154,613)for the three and nine months ended August 31, 2002 as well as reporting net losses of $ (5,009,798)from inception (December 24, 1997) to August 31, 2002. As reported on the statement of cash flows, the Company had negative cash flows from operating activities of $(58,978)for the nine months ended August 31, 2002 and has reported deficient cash flows from operating activities of $(2 590 597) from inception (December 24, 1997). To date, these losses and cash flow deficiencies have been financed principally through the sale of common stock $957,701 and short term debt $1,416,045 which is principally related party debt. Additional capital and/or borrowings will be necessary in order for the Company to continue in existence until attaining and sustaining profitable operations. Management has continued to develop a strategic plan, maintain reporting compliance and establish long term relationships with other major organizations to develop and distribute the product Malarex. Management anticipates generating revenue through the sales of Malarex(TM) during this fiscal year. The major shareholder's of the organization have committed to fund the operations of the organization during this fiscal year until the organization can generate sufficient cash flow from operations to meet current operating expenses and overhead. NOTE 5 - ACQUISITION OF SWORD COMP-SOFT On May 29, 2000, the company issued 5,000,000 shares of common stock in exchange for 35,700,000 shares of Sword Comp-Soft, Corp., a Delaware corporation which provides on-line interactive health services through the internet. The transaction was recorded using the "purchase method" as the registrant acquired 76.45% of Sword Comp-Soft, Corp.'s outstanding shares at May 29, 2000. NOTE 6 - STOCKHOLDER'S EQUITY Between December 2, 2001 and February 14, 2002 the company sold 613,750 shares of common stock at a price of $0.125 per share pursuant to Regulation S. The aforementioned $76,719 from stock sales have not yet been received by the corporation and is recorded as a diminution of shareholder's equity as a share subscription receivable. On February 14, 2002 the company sold 125,000 shares of common stock at a price of $0.125 per share pursuant to Regulation S. Between April 11, 2002 and May 3, 2002 the company issued 656,250 shares of common stock, pursuant to Regulation S in settlement of general and administrative expenses and other development costs. The total amount of these expenses was $ 78,750. On June 5, June 21 and on August 16, 2002 the company issued a total of 367,780 shares of common stock, pursuant to Regulation S in settlement of general and administrative expenses. The total amount of these expenses was $ 50,489. NOTE 7 - PATENT RIGHTS On May 31, 2001, Millenia Hope and Liquid Asset Corp signed a finalized purchase agreement that gives Millenia Hope the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 years period. The purchase price for these rights to September 1, 2005, is $ 500,000 cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of its subsidiary, Sword Comp-Soft Corp, that were owned by Millenia. NOTE 8 - OTHER ASSETS On October 9, 2001, Millenia Hope acquired a 68% interest in assets, comprised of land, plant and equipment located in Brazil to be used in the production of MalarexTM. The purchase price was $500,00 cash, 7 million Millenia Hope shares and 1 million non-registered common shares of its subsidiary, Sword Comp-Soft Corp, that were owned by Millenia. Plan of Operation The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product. Some of the statements under "Plan of Operations," "Business" and elsewhere in this registration statement are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements about our plans, objectives, expectations, intentions and assumptions and other statements contained herein that are not statements of historical fact. You can identify these statements by words such as "may," "will," "should," "estimates," "plans," "expects," "believes," "intends" and similar expressions. We cannot guarantee future results, levels of activity, performance or achievements. Our actual results and the timing of certain events may differ significantly from the results discussed in the forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements. The business objective of Millenia is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREXTM is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the affected market. The availability and pricing of MALAREXTM, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREXTM To date, Malarex(TM) has had positive test results for its efficacy and non-toxicity (Institute of Superior Health, University of Rome, Mcgill University, ITR Laboratories) and successful human trials (Mozambique 1997, Madagascar 1998, Cameroon 1999 and 2001). On September 26, 2000 Millenia's PCT (International)Patent Application was accepted and Millenia is now in the process of registering its patent protection on the National level (52 countries). As well, Malarex(TM) trademark application are pending in the aforementioned 52 countries. As of August 31, 2002, Millenia Hope had received 5 sales authorizations from West African nations, Congo (Brazzaville), Guinea (Conakry), Togo, Rwanda, the Central African Republic and product authorization from Burundi. We are awaiting sales authorizations from a number of other West African nations. Based on management's best estimates, Millenia hopes to sell 1 million treatments of Malarex or $ 7 million within 12 months of these authorizations having been received. Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately. It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% (between $180-$200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurances can be given that the Company will meet its sales goals. Furthermore, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As an integral part of this effort, Millenia will collaborate with major research centers as well as governmental and non-governmental organizations. There is currently insufficient funds to adequately provide for the Company's needs over the next twelve months, however, the officers and certain shareholders have committed to fund the operations of the company during the next twelve months until the company can generate sufficient cash flows from operations to meet current operating expenses and overhead. Liquidity and cash flow needs of the company From December 1st, 2001 to August 31, 2002 the company and its subsidiary incurred operating and interest expenses in the amount of $480,541 while recording net cash revenues of $317,586. from September 1st, 2002 to November 30th, 2002, the fiscal year end, the company anticipates that its net cash flow needs, including that of its subsidiary, will be $175,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined. SWORD COMP-SOFT CORP. an (ASP) Application Service Provider, incorporated in November 1998 specializing in the E-Healthcare sector, commenced activities in February 2000. Sword has what it believes is some of the most advanced technology currently available in the field of e-Healthcare and that it will be in a position to offer a range of application services designed around the concept of providing a series of useful, on line interactive health services and facilities in an attractive, convenient format to people in their electronic environments. These application services include the identification and personal logging of disease(s) and strategies to cope with long term health issues from nutrition, wellness and health in a "patient driven" format. Sword has completed the first phase of its first ASP which will be available over the Internet by October 31, 2002. Sword has already generated revenue and at its November 30, 2001 year end Sword, per its best estimates, expect to generates a net profit by its November 30, 2002 year end. Sword's registration statement was accepted by the Security Exchange Commission of the United States on July 16, 2001 and is a reporting company. It is presently in the process of applying to the appropriate authorities to be able to trade Sword shares in the public market place. Millenia had no affiliation with Sword prior to its successful negotiation with that company to purchase a controlling interest in it. Mr. Leonard Stella, chief operating officer of Millenia Hope, fills the same post at Sword as well as sitting on its Board of Directors. This allows Millenia to both monitor and guide Sword in its financial transactions and decisions. On October 9, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. signed a purchase agreement via which Millenia acquired 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that were owned by Millenia. Cibecol, incorporated and headquartered in Brazil, operates one of the largest phyto-pharmaceutical plants in Southern Brazil out of its 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located in Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of voacamine, the active agent in Malarex(TM). Millenia, under the leadership of its scientific committee, expects to introduce a new concept, called 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream. As per the January 1999 article in the Canadian Journal of Health & Nutrition titled, "Oxygen Boosts Performance", the benefits of additional oxygen for the body are numerous. Cardiovascular endurance, especially if the patient has heart or pulmonary problems, heads this list. Added supplies of oxygen raises the human body's energy levels, gives greater muscular endurance, improves concentration, calms the nervous system and helps in the removal of toxins. These benefits are of extreme importance to ambulatory patients, as their body is not getting the exercise that is so necessary to proper oxygen consumption. The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion. On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which gave Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia. Liquid Asset, a manufacturer of oxygenated and specialized beverages, was incorporated on November 29, 1999 and commenced activities in September 2000. Mr. Leonard Stella, Chief Operating Officer of Millenia Hope, fills the same position with Liquid Asset Corp. as well as sitting on its Board of Directors. Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies. Part II other information Item 2: Sales of Unregistered securities
Date of Title of Number Consideration Exemption from Sale Security Sold Received Registration claimed 12/02/2001 common shares 25,000 $3,125 Regulation S 1/10/2002 common shares 250,000 $31,250 Regulation S 1/17/2002 common shares 68,750 $8,594 Regulation S 1/24/2002 common shares 145,000 $18,125 Regulation S 2/14/2002 common shares 250,000 $31,250 Regulation S 4/11/2002 common shares 372,600 Settlement Regulation S General and Administrative Expenses $ 44,712 4/25/2002 common shares 270,000 Settlement Regulation S Other Development Costs $ 32,400 5/03/2002 common shares 13,650 Settlement Regulation S General and Administrative Expenses $ 1,638 6/05/2002 common shares 242,780 Settlement Regulation S General and Administrative Expenses $ 33,989 6/21/2002 common shares 100,000 Settlement Regulation S General and Administrative Expenses $ 14,000 8/16/2002 common shares 25,000 Settlement Regulation S General and Administrative Expenses $ 2,500 (b) Reports on Form 8-K None
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Millenia Hope Inc. (Registrant) Dated October 15, 2002 By: /s/ Dominique Morisot ---------------------- President / CEO -----END PRIVACY-ENHANCED MESSAGE-----